“Our transposon-, and transposase-based platform has direct applications in recombinant protein expression, cell line development and cell/gene therapy,” said Claes Gustafsson, PhD, ATUM’s Chief Commercial Officer. “We have already seen strong interest from protein pharmaceutical companies in our proprietary tools for transient and stable protein production in mammalian hosts. Now more than ever, we are in a position to apply our bioengineering tools to the entire spectrum of bioengineering, from designing and building better genes, proteins and pathways all the way to genomes.”
“This key Leap-In patent validates the genome engineering platform we’re building,” said Jeremy Minshull, PhD, CEO of ATUM. “We are committed to expand our recombinant protein and antibody expression suite of tools for both transient and stable mammalian protein production. Our unique and expanding Leap-In transposon patent estate in combination with our operational focus on our new state-of-the-art mammalian protein and antibody production laboratory enable efficient industrial scale biomanufacturing.”
ATUM currently has 21 issued US patents covering bioengineering of genes, proteins, genomes and more.
ATUM is the leading bioengineering solutions provider, offering an integrated pipeline of tools including gene design, optimization and synthesis, expression vectors, and platforms for protein and cell line engineering and production. ATUM explores novel applications for synthetic genes and the synergy between efficient gene design and protein optimization technologies. ATUM’s tools and solutions are fueling the transformation of biology from a discovery science to an engineering discipline. The company is privately held and is headquartered in Newark, California. For more information, please visit ATUM http://www.atum.bio.
Lisa Lilienthal, 404-661-3679